• Innate Pharma announces today its tentative financial and investor relations calendar for 2010.
• The Company also announces today the settlement and delivery of its capital increase reserved to categories of investors announced on December 18, 2009. 10,724,535 new shares were issued. The gross proceeds amount to 24.3 million euros (issuance premium included) and the net proceeds amount to 23.1 million euros.

Following the transaction, Novo Nordisk A/S, the Fonds stratégique d’investissement (FSI) and Alta Partners are the main shareholders of the Company with respectively 15.21%, 13.23% and 7.41% of the share capital and voting rights of the Company.

The appointment of a representative of the FSI to the Supervisory Board of the Company will be proposed at the next Shareholder’s Meeting.

All corporate information on the company such as its financial statements or its corporate presentations is available on the company’s website, in the investor documentation centre, Investors’ section.